BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aqua Bounty, Recalcine Farmaceutica In Drug Development Deal


10/19/2005 5:08:56 PM

WALTHAM, Mass., July 6 /PRNewswire/ -- A leading North American developer of aquatic biotechnology products and the largest privately-held pharmaceutical company in South America will cooperate in the discovery, development and commercialization of new veterinary vaccines, antimicrobial agents and diagnostic products targeting shrimp and salmon diseases characteristic of the southern hemisphere.

In a wide-ranging agreement that leverages the companies' complementary strengths, U.S.-Canadian-based Aqua Bounty Technologies (ABT) and Recalcine Farmaceutica (CFR) of Santiago, Chile will develop, manufacture and market a range of aquatic veterinary products targeted to infective species and strains specific to South America. The companies also agreed to create several regional diagnostic centers in shrimp and salmon farming areas to bring powerful new quantitative PCR and molecular probe techniques to the South American market.

"South America has embraced the Blue Revolution," said Alejandro Weinstein, the chief executive officer of CFR. "As aquaculture producers increase their volume, acquire new species and expand into new locations, effective biosecurity and best health management practices will be essential for long term stability in the industry. The strategic alliance between Recalcine and Aqua Bounty will provide farmers with the tools they need through the entire production process to detect, prevent and ultimately to cure the diseases that threaten sustainable production."

Under the agreement, ABT will develop or improve vaccines for up to five significant salmon pathogens and develop an antifungal treatment for salmon eggs and fry to be distributed by CFR. The pharmaceutical company will also introduce ABT's shrimp diagnostic kits, currently available in Asia, to the South American market. The kits are capable of detecting a single strand of pathogenic DNA in shrimp and will, under the agreement, be expanded in application to detect disease in salmon as well. The agreement also allows CFR to market ABT's shrimp immunostimulant feed additive, currently available only in Mexico, to South American markets to be determined.

CFR will finance the development costs, contribute milestone payments to fund field trials and market the full suite of shrimp and salmon health products through its established sales network.

CONTACT: Joseph McGonigle 781-899-7755 http://www.aquabounty.com/

Aqua Bounty Technologies

CONTACT: Joseph McGonigle of Aqua Bounty Technologies, +1-781-899-7755



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES